|
|
|
|
|
|
|
||
J. Exp. Med.,
Volume 188, Number 1, July 1, 1998 17-27
By
From the * MediCity Research Laboratories, University of Turku, FIN-20520 Turku, Finland; the Vascular adhesion protein 1 (VAP-1) is a human endothelial sialoglycoprotein whose cell surface expression is induced under inflammatory conditions. It has been shown previously to participate in lymphocyte recirculation by mediating the binding of lymphocytes to peripheral
lymph node vascular endothelial cells in an L-selectin-independent fashion. We report here
that the VAP-1 cDNA encodes a type II transmembrane protein of 84.6 kD with a single
transmembrane domain located at the NH2-terminal end of the molecule and six potential N-glycosylation sites in the extracellular domain. In vivo, the protein exists predominantly as a
homodimer of 170-180 kD. Ax endothelial cells transfected with a VAP-1 cDNA express
VAP-1 on their cell surface and bind lymphocytes, and the binding can be partially inhibited
with anti-VAP-1 mAbs. VAP-1 has no similarity to any currently known adhesion molecules,
but has significant identity to the copper-containing amine oxidase family and has a monoamine
oxidase activity. We propose that VAP-1 is a novel type of adhesion molecule with dual function. With the appropriate glycosylation and in the correct inflammatory setting, its expression on the lumenal endothelial cell surface allows it to mediate lymphocyte adhesion and to function as an adhesion receptor involved in lymphocyte recirculation. Its primary function in
other locations where it is expressed, such as smooth muscle, may depend on its inherent monoamine oxidase activity.
National Public Health Institute, FIN-20520 Turku, Finland; and the § Centre for Biotechnology,
BioCity, FIN-20520 Turku, Finland
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
| TABLE OF CONTENTS |
|
